Ravulizumab To Protect Patients with Chronic Kidney Disease (CKD) From Cardiac Surgery Associated Acute Kidney Injury (CSA-AKI) and Subsequent Major Adverse Kidney Events (MAKE): A Phase 3, Randomized

Activity Type
Clinical Trial
Date
Dollar Amount
*
Grant Type
Contract
Principal Investigator
Toshinobu Kazui
Sponsor
Alexion Pharmaceuticals, Incorporated
Unit
Surgery